Central Pacific Bank Trust Division Takes $502,000 Position in Repligen Co. (NASDAQ:RGEN)

Central Pacific Bank Trust Division bought a new stake in shares of Repligen Co. (NASDAQ:RGEN) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,743 shares of the biotechnology company’s stock, valued at approximately $502,000.

Several other large investors also recently modified their holdings of RGEN. YHB Investment Advisors Inc. acquired a new position in Repligen in the first quarter worth about $26,000. Benjamin F. Edwards & Company Inc. grew its stake in Repligen by 152.1% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 146 shares in the last quarter. Principal Securities Inc. acquired a new position in Repligen in the fourth quarter worth about $48,000. CWM LLC grew its stake in Repligen by 19.9% in the first quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 60 shares in the last quarter. Finally, Signaturefd LLC grew its stake in Repligen by 48.4% in the fourth quarter. Signaturefd LLC now owns 417 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 136 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently commented on RGEN. Guggenheim began coverage on Repligen in a research note on Tuesday, June 18th. They issued a “neutral” rating for the company. Deutsche Bank Aktiengesellschaft upgraded Repligen from a “hold” rating to a “buy” rating and decreased their target price for the company from $180.00 to $155.00 in a research note on Wednesday, June 26th. Finally, JPMorgan Chase & Co. decreased their target price on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $193.00.

Insider Buying and Selling

In related news, CEO Anthony Hunt sold 20,072 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the sale, the chief executive officer now owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Martin D. Madaus purchased 1,615 shares of the company’s stock in a transaction on Friday, June 14th. The shares were bought at an average price of $124.94 per share, with a total value of $201,778.10. Following the completion of the acquisition, the director now owns 4,613 shares of the company’s stock, valued at $576,348.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Anthony Hunt sold 20,072 shares of the company’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the transaction, the chief executive officer now directly owns 163,177 shares in the company, valued at approximately $27,456,162.02. The disclosure for this sale can be found here. 1.20% of the stock is owned by corporate insiders.

Repligen Stock Performance

Shares of RGEN traded down $0.22 during mid-day trading on Wednesday, reaching $120.60. 25,637 shares of the company’s stock traded hands, compared to its average volume of 590,626. The business’s 50-day moving average price is $145.44 and its 200-day moving average price is $170.98. The stock has a market capitalization of $6.74 billion, a P/E ratio of 483.30, a price-to-earnings-growth ratio of 4.01 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.35. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $211.13.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The business had revenue of $151.31 million for the quarter, compared to the consensus estimate of $150.06 million. During the same period last year, the firm posted $0.64 EPS. The business’s quarterly revenue was down 17.1% on a year-over-year basis. Equities analysts predict that Repligen Co. will post 1.46 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.